Company: HCTI
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076686
Chunk: 38

Company: Healthcare Triangle, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
 to common stockholders 
    $(3,068) 
    $(3,372)
  
    Weighted average shares outstanding – basic and diluted(#) 
     1,197,824  
     19,622 
  
    Basic and diluted EPS 
    $(2.56) 
    $(171.85)

#Due to net loss position, basic and diluted weighted average
shares outstanding are the same.

17) Subsequent Events

The Company effected a [1-for 249]
reverse split of its issued and outstanding common stock on August 01, 2025. The reverse split reduced the number of issued and outstanding
shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share.

18) New
Accounting Pronouncements  

In March 2024, the FASB issued ASU No. 2024-01,
“Compensation—Stock Compensation (Topic 718): Scope Applications of Profits Interests and Similar Awards” (“ASU
2024-01”). ASU 2024-01 adds an example to Topic 718 which illustrates how to apply the scope guidance to determine whether profits
interests and similar awards should be accounted for as share-based payment arrangements under Topic 718 or under other U.S. GAAP. ASU
2024-01 is effective for annual periods beginning after December 15, 2025, although early adoption is permitted. Upon adoption, ASU 2024-01
is not expected to have an impact on the Company’s consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03,
“Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40).” This standard
requires disclosure of specific information about costs and expenses and becomes effective January 1, 2027. The Company is currently evaluating
the impact of this standard on our consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-04,
“Debt - Debt with Conversions and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments” (“ASU
2024-04”). ASU 2024-04 clarifies the requirements for determining whether certain settlements of convertible debt instruments, including
convertible debt instruments with cash conversion features or convertible debt instruments that are not currently convertible, should
be